ANAPTYSBIO, INC. Foreign Currency Transaction Gain (Loss), before Tax
ANAPTYSBIO, INC. (ANAB) reported Foreign Currency Transaction Gain (Loss), before Tax of $200.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-05.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2018-03-05
- ANAPTYSBIO, INC. foreign currency transaction gain (loss), before tax for fiscal 2017 was $200.00K.
- ANAPTYSBIO, INC. foreign currency transaction gain (loss), before tax for fiscal 2016 was -$100.00K.
- ANAPTYSBIO, INC. foreign currency transaction gain (loss), before tax for fiscal 2015 was -$200.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|
| 2017-12-31 | $200.00K 10-K · filed 2018-03-05 |
| 2016-12-31 | -$100.00K 10-K · filed 2018-03-05 |
| 2015-12-31 | -$200.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |